OEM Customer Loss Drives Revenue Miss on Syneron Medical Ltd (ELOS); Leerink Partners Cuts Price Target to $9.40
Tweet Send to a Friend
Leerink Partners maintained an Outperform rating on Syneron Medical (NASDAQ: ELOS), and cut the price target to $9.40 (from $16.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
